Sign in with Google
bullish
2023 High Conviction Update: Cipla (CIPLA IN)- Strong US Business Drove Q4 Result Amid Uncertainty
589 Views16 May 2023 10:30
Boomeranged on Sat, 1 Jul 2023 06:03
Since reporting Q4 results, Cipla shares gained 10%+, showing early signs of revival. The company is seeing some recoveries in the generic prices in the U.S. compared to last year. Moreover, concern over the FDA action on the company's manufacturing facility impacting revenue seems to be overdone. Cipla is well-positioned to leverage on its complex and niche respiratory generics portfolio.
SUMMARY
- IN Q4FY23, Cipla Ltd (CIPLA IN) reported highest ever US business revenue of $204M, up 27% YoY and 5% QoQ, driven by expansion in market share of key launches.
- Lead peptide asset Lanreotide injection, launched in Q4FY22, is consistently gaining market share. The product currently has market share of 17%, up from 14.1% in Q3FY23 and 9.6% in Q2FY23.
- Ex-COVID, India business revenue increased 16% YoY, driven by chronic branded prescription portfolio. FY23 marks the second consecutive year of market beating growth of Cipla’s chronic portfolio.
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »Loading
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Cipla (CIPLA IN): Q3FY24 Result- Continued Growth Trajectory Across Key Markets; Positive Outlook30 Jan 2024
- 2023 High Conviction Update: Cipla (CIPLA IN)- Q2 Result Beats Estimates; Margin Guidance Raised02 Nov 2023
- 2023 High Conviction Update: Cipla (CIPLA IN)- Stellar Q1FY24 Performance; Margin Guidance Raised29 Jul 2023
- 2023 High Conviction Update: Cipla (CIPLA IN)- Strong Traction Continued in Q3; Record High US Sales29 Jan 2023
- 2023 High Conviction Idea: Cipla (CIPLA IN)- Complex Generics and India Business to Drive Growth08 Nov 2022
x